INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 53 filers reported holding INOZYME PHARMA INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,405,518 | -16.0% | 334,647 | +11.4% | 0.00% | – |
Q2 2023 | $1,673,133 | +536.4% | 300,383 | +554.7% | 0.00% | – |
Q1 2023 | $262,903 | +445.0% | 45,882 | -0.1% | 0.00% | – |
Q4 2022 | $48,240 | -55.3% | 45,943 | +14.0% | 0.00% | – |
Q3 2022 | $108,000 | -51.8% | 40,304 | -14.2% | 0.00% | – |
Q2 2022 | $224,000 | -51.9% | 46,990 | -58.7% | 0.00% | – |
Q1 2022 | $466,000 | -43.4% | 113,823 | -5.7% | 0.00% | – |
Q4 2021 | $823,000 | -38.8% | 120,762 | +4.0% | 0.00% | – |
Q3 2021 | $1,345,000 | -34.6% | 116,101 | -3.8% | 0.00% | – |
Q2 2021 | $2,057,000 | -10.0% | 120,743 | +4.6% | 0.00% | – |
Q1 2021 | $2,286,000 | +19.4% | 115,469 | +24.4% | 0.00% | – |
Q4 2020 | $1,915,000 | -21.5% | 92,806 | +0.0% | 0.00% | -100.0% |
Q3 2020 | $2,439,000 | – | 92,764 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $18,441,000 | 6.52% |
CHI Advisors LLC | 920,264 | $10,666,000 | 3.11% |
Sofinnova Investments, Inc. | 2,028,308 | $23,508,000 | 1.39% |
MPM BioImpact LLC | 320,724 | $3,717,000 | 0.58% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $27,176,000 | 0.53% |
NEA Management Company, LLC | 2,444,379 | $28,330,000 | 0.34% |
Rock Springs Capital Management LP | 850,015 | $9,852,000 | 0.21% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 986,400 | $11,432,000 | 0.19% |
Overbrook Management Corp | 16,726 | $194,000 | 0.04% |
Orbimed Advisors | 294,000 | $3,407,000 | 0.04% |